$23.6MSeries B, 10 February 2026
First close of Series B to advance DT-7012 and finish preclinical work on DT-9046.
- Amount
- $23.6M
- Stage
- Series B
- Announced
- 10 February 2026
- Lead
- Investissement Québec
- Other investors
- CTI Life Sciences, Panacea Venture, 3B Future Health Fund, Seventure Partners, Viva BioInnovator, Turenne Capital, Schroders Capital, adMare
- Use of funds
- First close of Series B to advance DT-7012 and finish preclinical work on DT-9046.
- Checked
- Announced by the company
- Sources
- Kainova Therapeutics raises C$32M Series B for immuno-oncology drug development biospace.com
Kainova Therapeutics raises C$32M Series B for immuno-oncology drug development pulse2.com